Literature DB >> 25139254

Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child.

Elaine O'Meara1, Deirdre Stack, Susan Phelan, Naomi McDonagh, Lorna Kelly, Raf Sciot, Maria Debiec-Rychter, Thomas Morris, Doug Cochrane, Poul Sorensen, Maureen J O'Sullivan.   

Abstract

Undifferentiated spindle cell sarcoma (UDS) is a poorly defined or understood entity, essentially a waste-basket for cases failing to fulfill criteria for better-established diagnoses based on combined histology, immunohistochemistry, and tumor genetic assays. We identified a novel chromosomal translocation t(17;19)(p13;q13) in a pediatric UDS and have characterized this alteration to show rearrangement of the MLL4 and GPS2 genes, resulting in an in-frame fusion gene MLL4-GPS2, the expression of which promotes anchorage-independent growth. MLL4 was previously reported to be similarly rearranged in hepatocellular carcinomas, notably those positive for hepatitis B virus. Isolated reports of individual rearrangements of GPS2 in a prostate carcinoma cell line and in glioblastoma multiforme, each with different partner genes, recently emerged from high-throughput sequencing studies but have not been further evaluated for biological effect.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Health Research Board of Ireland (CSA/2012/13); National Children's Research Centre

Mesh:

Substances:

Year:  2014        PMID: 25139254     DOI: 10.1002/gcc.22208

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.

Authors:  Madeline M Wong; Chun Guo; Jinsong Zhang
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

2.  Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group.

Authors:  Theodore W Laetsch; Angshumoy Roy; Lin Xu; Jennifer O Black; Cheryl M Coffin; Yueh-Yun Chi; Jing Tian; Sheri L Spunt; Douglas S Hawkins; Julia A Bridge; D Williams Parsons; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

Review 3.  Targeting human SET1/MLL family of proteins.

Authors:  Masoud Vedadi; Levi Blazer; Mohammad S Eram; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Taraneh Hajian
Journal:  Protein Sci       Date:  2017-03-06       Impact factor: 6.725

4.  Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma.

Authors:  Selena Y Lin; Adam Zhang; Jessica Lian; Jeremy Wang; Ting-Tsung Chang; Yih-Jyh Lin; Wei Song; Ying-Hsiu Su
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

5.  G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.

Authors:  Xiao-Dong Huang; Feng-Jun Xiao; Shao-Xia Wang; Rong-Hua Yin; Can-Rong Lu; Qing-Fang Li; Na Liu; Ying Zhang; Li-Sheng Wang; Pei-Yu Li
Journal:  Tumour Biol       Date:  2016-07-26

6.  G protein pathway suppressor 2 suppresses gastric cancer by destabilizing epidermal growth factor receptor.

Authors:  Yuan Si; Haitao Zhang; Peng Peng; Chu Zhu; Jie Shen; Yilian Xiong; Xuewen Liu; Yuchen Xiang; Wenjuan Li; Yuliang Ren; Fang Wan; Liang Zhang; Ying Liu
Journal:  Cancer Sci       Date:  2021-10-20       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.